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Substantial evidence indicates that the 
immune system participates in cancer 
pathogenesis and may either contrib-
ute to disease progression or potently 
inhibit tumor growth. On one hand, 
regressing tumor lesions are often mark-
edly infiltrated by mononuclear cells and 
the presence of T lymphocytes has been 
associated with improved prognosis in 
patients affected by different types of 
cancer.1 On the other hand, tumor infil-
tration by T-lymphocyte subsets endowed 
with immunoregulatory or suppressive 
potential has been associated with tumor 
progression and unfavorable prognosis.1 
Although most studies on the role of the 
immune system in oncogenesis, tumor 
progression and response to therapy have 
focused on CD8+ T cells, other lym-
phocyte subsets may be involved. Thus, 
understanding the role of different subsets 
of tumor-infiltrating immune cells in the 
pathogenesis of specific tumors is critical 
for the development of efficient antitumor 
immunotherapeutic strategies.
γδ T lymphocytes are important effec-
tor cells that may play a critical role in can-
cer immunosurveillance.2 In line with this 
notion, results from recent clinical trials 
support the use of γδ T cells as immuno-
therapeutic agents, either via the adoptive 
transfer of ex vivo expanded γδ T cells 
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or following the activation of γδ T cells 
in vivo, by means of compounds such as 
phosphoantigens or aminobisphospho-
nates.3 γδ T cells are heterogeneous and 
can be sub-divided into two main popula-
tions based on phenotypic and functional 
parameters: γδ T cells expressing the Vδ1 
T-cell receptor (TCR) chain, which are 
mostly found in mucosal tissues, and γδ 
T cells expressing the Vδ2 TCR chain, 
which predominate in the peripheral 
blood and secondary lymphoid organs. 
γδ T cells are endowed with a variety of 
effector functions that contribute to anti-
tumor immune responses. In particular, 
γδ T cells can mediated cytotoxic activ-
ity against cancer cells, produce T
H
1-
associated cytokines and cross-talk with 
dendritic cells, macrophages and B cells.4 
This said, under appropriate conditions, 
γδ T cells may divert from their typical 
T
H
1-like phenotype and polarize toward 
T
H
2, T
H
17, and regulatory T cells (Tregs),4 
all of which (at least potentially) inhibit 
antitumor immune responses.
Driven by these observations, we have 
recently evaluated the representation and 
functional characteristics of tumor-infil-
trating γδ T cells isolated from patients 
affected by primary melanoma and corre-
lated the levels of infiltrating γδ T cells with 
common clinicopathological features.5
Immune cells were detected in 70% of 
74 tissue specimens from primary mela-
noma patients, macrophages being the 
predominant cell population. γδ T cells 
were the major CD3+ T-lymphocyte sub-
set and Vδ1 and Vδ2 T cells were equally 
represented. The vast majority of mela-
noma-infiltrating Vδ1 and Vδ2 T cells 
exhibited an effector memory (T
EM
) or 
terminally differentiated effector memory 
(T
EMRA
) phenotype, which is indicative 
of cells that reside at or have migrated to 
sites of inflammation and display immedi-
ate effector functions.6 However, because 
the yield of primary γδ T cells isolated 
from melanoma lesions was very low and 
did not allow for detailed functional stud-
ies, we generated a panel of Vδ1 and Vδ2 
polyclonal γδ T-cell lines starting from 
the tumor-infiltrating immune cells of 8 
patients. All tested Vδ1 and Vδ2 T-cell 
lines were able to produce cytokines 
with proven antitumor activity, such as 
tumor necrosis factor α (TNFα) and 
interferon γ (IFNγ) and to kill melanoma 
cells in vitro, suggesting that both resident 
Vδ1 and recently migrated Vδ2 T cells 
may contribute to tumor growth control. 
However, we found substantial differences 
in the cytotoxic activity of Vδ1 and Vδ2 
T cells. In particular, while the majority of 
Vδ1 T-cell lines exerted potent cytotoxic 
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properties, which inhibit antitumor 
immune responses.4
There is thus an urgent need for addi-
tional prospective investigations of the rel-
evance of γδ T cells in different types of 
tumor, evaluating multiple structural and 
functional parameters. Such a knowledge 
will undoubtedly help in the determina-
tion of the most significant biomarkers 
to predict disease outcome and eventu-
ally guide γδ T cell-based tumor-specific 
immunotherapies.
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in a cohort of breast cancer patients the 
amount of intratumoral γδ T cells cor-
related positively with advanced tumor 
stages and lymph node metastasis, but 
inversely with both relapse-free and over-
all survival.8 Nowadays, we can only 
speculate on the discrepancy between 
results obtained in melanoma, renal cell 
carcinoma and breast cancer patients. 
The relative abundance of Vδ1 and Vδ2 
γδ T cells can only be discerned by the use 
of additional markers (cytokine produc-
tion, cytotoxic activity, migratory proper-
ties), implying that a positive or negative 
correlation with prognosis may depend 
on the specific γδ T-cell subset recruited 
at the tumor site (Fig. 1). Furthermore, 
the net biological effects of γδ T cells may 
depend on the tumor type and its anatom-
ical location, perhaps reflecting micro-
environmental differences. For instance, 
transforming growth factor β (TGFβ), 
which is abundantly secreted at the tumor 
site by tumor-infiltrating macrophages or 
malignant cells themselves, may favor the 
differentiation of γδ cells with Treg-like 
effects against melanoma cell lines in 
vitro, only a few Vδ2 T-cell lines were able 
to kill such targets.
In our study, the presence of γδ T cells, 
and in particular of the Vδ2 subset, 
among tumor-infiltrating immune cells 
significantly correlated with early stage 
melanoma, a finding that may stem, at 
least in part, from the limited efficacy of 
local immune responses at advanced dis-
ease stages. Of note, higher percentages of 
γδ T cells were detected in patients bear-
ing early (Stage 0–II) melanoma lesions 
and no metastases, whereas γδ cells were 
scarce in patients at an advanced disease 
stage (Stage III–IV) and bearing meta-
static lesions.
Recent studies have revealed a high 
frequency of γδ T cells among tumor-
infiltrating lymphocytes from patients 
affected by different types of cancer, but 
the clinical relevance of intratumoral γδ 
T cells remains unknown. Thus, while in 
one study the percentage of γδ T cells infil-
trating renal cell carcinoma lesions failed 
to correlate with prognostic features,7 
Figure 1. Potential role of γδ t cells in tumor control. teM, effector memory t cell; treg, regulatory t cell.
